Xie Li, Li You-Mei
Department of Cardiovascular Medicine, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
Int J Environ Res Public Health. 2017 Jan 16;14(1):84. doi: 10.3390/ijerph14010084.
In recent years, the lipoprotein lipase (LPL) polymorphism has been extensively investigated as a potential risk factor for coronary artery disease (CAD). However, the results of these studies have been inconsistent. Therefore, we performed this meta-analysis to explore the association between LPL polymorphism and CAD risk.
The literature was searched from electronic databases such as Embase, China Biological Medicine Database, PubMed, Knowledge Infrastructure, and China National Web of Science by the key words "coronary artery disease", "lipoprotein lipase" and "polymorphism". All of the studies included in this manuscript met the inclusion and exclusion criteria. An odds ratio (OR) analysis using a 95% confidence interval (CI) was employed to assess the association of the LPL polymorphism with CAD susceptibility.
We performed a meta-analysis of 14 case-control studies including HindIII, Ser447X and PvuII polymorphism. A statistically significant increase in the risk of CAD was associated with LPL HindIII polymorphism. This included HindIII H⁺H⁺ genotype (OR = 1.28, 95% CI = 1.09-1.49, = 0.002, I² = 43%) and H⁺ allele genotype (OR = 1.27, 95% CI = 1.03-1.58, = 0.03, I² = 67%). Ser447X XX genotype (OR = 2.37, 95% CI = 1.33-4.24, = 0.004, I² = 53%) was also associated with CAD risk. However, PvuII polymorphism was found to have no significant association with CAD risk.
LPL HindIII polymorphism was significantly associated with the risk of CAD. For Ser447X polymorphism, it was found that only XX genotype was significantly associated with CAD risk. Furthermore, PvuII polymorphism had no significant association with CAD risk. It was considered that LPL HindIII polymorphism might serve as a potential biomarker for CAD risk.
近年来，脂蛋白脂肪酶（LPL）基因多态性作为冠状动脉疾病（CAD）的潜在危险因素受到广泛研究。然而，这些研究结果并不一致。因此，我们进行了这项荟萃分析，以探讨LPL基因多态性与CAD风险之间的关联。
通过关键词“冠状动脉疾病”、“脂蛋白脂肪酶”和“多态性”在Embase、中国生物医学数据库、PubMed、知网和中国科学文献数据库等电子数据库中检索文献。本研究纳入的所有研究均符合纳入和排除标准。采用比值比（OR）分析及95%置信区间（CI）来评估LPL基因多态性与CAD易感性的关联。
我们对14项病例对照研究进行了荟萃分析，包括HindIII、Ser447X和PvuII基因多态性。CAD风险显著增加与LPL HindIII基因多态性有关。这包括HindIII H⁺H⁺基因型（OR = 1.28，95% CI = 1.09 - 1.49，P = 0.002，I² = 43%）和H⁺等位基因基因型（OR = 1.27，95% CI = 1.03 - 1.58，P = 0.03，I² = 67%）。Ser447X XX基因型（OR = 2.37，95% CI = 1.33 - 4.24，P = 0.004，I² = 53%）也与CAD风险相关。然而，发现PvuII基因多态性与CAD风险无显著关联。
LPL HindIII基因多态性与CAD风险显著相关。对于Ser447X基因多态性，发现只有XX基因型与CAD风险显著相关。此外，PvuII基因多态性与CAD风险无显著关联。认为LPL HindIII基因多态性可能作为CAD风险的潜在生物标志物。
Zotero 插件
